Breathtec Biomedical Provides Update on Lead Project and In-Licensing Discussions

Vancouver, British Columbia, CANADA

VANCOUVER, BC--(Marketwired - Apr 4, 2016) - Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (the "Company" or "Breathtec"), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of life threatening diseases, is pleased to provide an update on the status of the Company's lead project; the miniaturization of a Field Asymmetric Ion Mobility Spectrometry (FAIMS) device and ongoing discussions with potential partners aimed at in-licensing synergistic and/or complementary clinical stage intellectual property and technology.


The Company has partnered with Dr. Rick Yost, a professor at the University of Florida, to develop highly portable point of care breath testing devices. Breathtec's efforts are aimed at developing hand held breath test devices that can be used in medical facilities for early screening of diseases such as lung and breast cancers, neurodegenerative diseases (e.g.: Alzheimer's and/or Parkinson's), tuberculosis, diabetes, liver disease, infections and more.

Richard A. Yost Ph.D., Scientific Advisor

Dr. Yost is the Colonel Allen R. and Margaret G. Crow Professor and Head of Analytical Chemistry at UF, as well as the Director of the NIH Southeast Center for Integrated Metabolomics. He is highly qualified in the field of mass spectrometry, and his research has involved over 100 graduate students funded by over $50 million in research grants. He has published over 175 papers and 16 patents. Dr. Yost designed the existing triple quadrupole mass spectrometer, and over $30 billion worth of instruments have been sold based on this technology. He has served as a member of the Florida Board of Governors (Regents) and the UF Board of Trustees. He has served as Treasurer and Secretary (and was recently elected Vice President) of the American Society for Mass Spectrometry, and on the editorial boards of The Journal of the American Society for Mass Spectrometry and The International Journal of Mass Spectrometry.

Breathtec is pleased to update that the development of the miniaturized breath test device is progressing well under Dr. Yost's supervision. Many proprietary components required for hand held breath testing, such as a high-voltage generator, non-radioactive ionization source, and array detector are being integrated with the novel FAIMS cell to provide the most technologically advanced FAIMS-based instrument in the world.

"We expect to have a prototype of the FAIMS device developed in Q3-Q4 of 2016 and will work alongside our partner to advance the technology towards the clinic. We are pleased with the progress our team has made thus far and are encouraged by the early data we are seeing," said Dr. Michael Costanzo, CEO of Breathtec. "The clinical benefit of a hand-held screening device has garnered overwhelmingly positive feedback from our peers and practitioners in the health care community."

In-Licensing and Acquisitions

For the past several months, alongside advancing the FAIMS technology, the Company has been actively engaged in reviewing complementary and/or synergistic advanced and clinical stage intellectual property and technologies for the purpose of in-licensing or acquisition. After thorough review by the Company's management team and scientific advisors, a short list has been identified. "We expect to execute a definitive agreement (in-license or acquisition) of our first advanced stage technology in Q2-2016. Our goal is to build a pipeline of assets that offer mid and near term commercial applicability and the ability to create and deliver value for shareholders," said Dr. Costanzo.

For more information, please visit:


"Kal Malhi"
President & Director

CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

Contact Information:

For further information, please contact:
CORE Capital Partners
Telephone: 604-566-9233